JP2022515330A5 - - Google Patents

Info

Publication number
JP2022515330A5
JP2022515330A5 JP2021531831A JP2021531831A JP2022515330A5 JP 2022515330 A5 JP2022515330 A5 JP 2022515330A5 JP 2021531831 A JP2021531831 A JP 2021531831A JP 2021531831 A JP2021531831 A JP 2021531831A JP 2022515330 A5 JP2022515330 A5 JP 2022515330A5
Authority
JP
Japan
Application number
JP2021531831A
Other languages
Japanese (ja)
Other versions
JP2022515330A (ja
JP7549579B2 (ja
JPWO2020132297A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067575 external-priority patent/WO2020132297A1/en
Publication of JP2022515330A publication Critical patent/JP2022515330A/ja
Publication of JP2022515330A5 publication Critical patent/JP2022515330A5/ja
Publication of JPWO2020132297A5 publication Critical patent/JPWO2020132297A5/ja
Application granted granted Critical
Publication of JP7549579B2 publication Critical patent/JP7549579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531831A 2018-12-19 2019-12-19 多量体t細胞調節ポリペプチド及びその使用方法 Active JP7549579B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782167P 2018-12-19 2018-12-19
US62/782,167 2018-12-19
US201962814684P 2019-03-06 2019-03-06
US62/814,684 2019-03-06
PCT/US2019/067575 WO2020132297A1 (en) 2018-12-19 2019-12-19 Multimeric t-cell modulatory polypeptides and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022515330A JP2022515330A (ja) 2022-02-18
JP2022515330A5 true JP2022515330A5 (https=) 2022-12-26
JPWO2020132297A5 JPWO2020132297A5 (https=) 2022-12-26
JP7549579B2 JP7549579B2 (ja) 2024-09-11

Family

ID=71100921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531831A Active JP7549579B2 (ja) 2018-12-19 2019-12-19 多量体t細胞調節ポリペプチド及びその使用方法

Country Status (18)

Country Link
US (2) US20220112252A1 (https=)
EP (2) EP4650365A3 (https=)
JP (1) JP7549579B2 (https=)
KR (1) KR20210104673A (https=)
CN (1) CN113286609B (https=)
AU (1) AU2019404285B2 (https=)
BR (1) BR112021011814A2 (https=)
CA (1) CA3113100A1 (https=)
DK (1) DK3897701T3 (https=)
ES (1) ES3052836T3 (https=)
IL (1) IL281505B1 (https=)
MX (1) MX2021007287A (https=)
MY (1) MY206813A (https=)
PH (1) PH12021500027A1 (https=)
SG (1) SG11202103863UA (https=)
SI (1) SI3897701T1 (https=)
TW (1) TWI856047B (https=)
WO (1) WO2020132297A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
EP4149953A4 (en) * 2020-05-12 2024-06-26 Lg Chem, Ltd. MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
EP4182465A4 (en) * 2020-07-14 2024-08-07 Cue Biopharma, Inc. T-CELL MODULATORY POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2022099157A1 (en) * 2020-11-06 2022-05-12 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
JP2024512470A (ja) * 2021-03-19 2024-03-19 キュー バイオファーマ, インコーポレイテッド T細胞調節ポリペプチド及びその使用方法
JP2024518680A (ja) * 2021-03-19 2024-05-02 キュー バイオファーマ, インコーポレイテッド T細胞調節ポリペプチド及びその使用方法
WO2023081718A1 (en) * 2021-11-04 2023-05-11 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN114805538B (zh) * 2022-05-20 2023-06-09 广州智瓴生物医药有限公司 一种增强til功效的培养方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US9205144B2 (en) 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
EP3769782A1 (en) * 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
PL3157552T3 (pl) * 2014-06-18 2020-05-18 Albert Einstein College Of Medicine Polipeptydy syntac i ich zastosowania
MY193723A (en) * 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
CA2978186A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
LT3377516T (lt) * 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
IL269000B2 (en) * 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
AU2018236461B2 (en) * 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
EP3678691A4 (en) * 2017-09-07 2021-06-09 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2020132365A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2021055594A1 (en) * 2019-09-20 2021-03-25 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
US20230117521A1 (en) * 2020-03-25 2023-04-20 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
JP2024512470A (ja) * 2021-03-19 2024-03-19 キュー バイオファーマ, インコーポレイテッド T細胞調節ポリペプチド及びその使用方法

Similar Documents

Publication Publication Date Title
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
JP2022515330A5 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021017728A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021017310A2 (https=)